SignalXSignalX

VERA Vera Therapeutics, Inc.

FY2025 10-K
Filed: Feb 26, 2026
Health Care
Pharmaceutical PreparationsSEC EDGAR
Vera Therapeutics, Inc. Overview

Vera Therapeutics, Inc. (VERA) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Risk Factors

  • • Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
  • • Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments
+3 more insights

Financial Summary
XBRL

Net Income

-$300M

ROE

-49.6%

Total Assets

$735M

EPS (Diluted)

$-4.66

Operating Cash Flow

-$241M

Source: XBRL data from Vera Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Vera Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available